{"success":true,"data":{"pressRelease":{"id":"169661","rtpr_id":"nBw8xSfqma-20261014","ticker":"IAM","exchange":"NASDAQ","all_tickers":["IAM"],"title":"Iambic Announces Pricing of Initial Public Offering","author":"Business Wire","published_at":"2026-10-14T22:53:00.098Z","article_body":"Iambic Announces Pricing of Initial Public Offering\n\nIambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life\nsciences and technology company advancing novel medicines using its AI-driven\nplatform, today announced the pricing of its initial public offering of\n9,375,000 shares of common stock at a public offering price of $16.00 per\nshare. All of the shares of common stock are being offered by Iambic. The\ngross proceeds from the offering, before deducting underwriting discounts and\ncommissions and other offering expenses payable by Iambic, are expected to be\n$150.0 million. In addition, Iambic has granted the underwriters a 30-day\noption to purchase up to an additional 1,406,250 shares of common stock at the\ninitial public offering price, less underwriting discounts and commissions.\nIambic’s common stock is expected to begin trading on the Nasdaq Global\nSelect Market on October 15, 2026, under the ticker symbol “IAM.” The\noffering is expected to close on October 16, 2026, subject to the satisfaction\nof customary closing conditions.\n\nJ.P. Morgan, Jefferies, BofA Securities and Citigroup are acting as joint\nbook-running managers for the offering.\n\nA registration statement relating to the offering has been filed with the\nSecurities and Exchange Commission and became effective on October 14, 2026.\nThe offering is being made only by means of a prospectus. A copy of the final\nprospectus, when available, relating to the offering will be available at\nwww.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54622422&newsitemid=20261014222850&lan=en-US&anchor=www.sec.gov&index=1&md5=06e0bce6dc5bafd4c7983d6fb5c076c6)\n. Copies of the final prospectus may also be obtained, when available, from:\nJ.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long\nIsland Avenue, Edgewood, New York 11717 or by email at\nprospectus-eq_fi@jpmchase.com (mailto:prospectus-eq_fi@jpmchase.com) ;\nJefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison\nAvenue, New York, New York 10022, by telephone at (877) 821-7388 or by email\nat Prospectus_Department@Jefferies.com\n(mailto:Prospectus_Department@Jefferies.com) ; BofA Securities, NC1-022-02-25,\nAttention: Prospectus Department, 201 North Tryon Street, Charlotte, North\nCarolina 28255-0001 or by email at dg.prospectus_requests@bofa.com\n(mailto:dg.prospectus_requests@bofa.com) ; or Citigroup Global Markets Inc.,\nc/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717 or by telephone at 1-800-831-9146.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation, or\nsale would be unlawful prior to the registration or qualification under the\nsecurities laws of any such state or jurisdiction.\n\nAbout Iambic\n\nIambic’s mission is to make better technology for better medicines. By\nutilizing molecular superintelligence — integrating proprietary AI with\nautomated, scalable chemistry and biology experimentation — our platform is\ndesigned to address the totality of drug discovery and development. We believe\nthe utility of our platform is demonstrated by the discovery of IAM1363, a\nnovel drug candidate advanced to clinic in approximately two years, along with\na diverse preclinical pipeline. Our leading AI technologies include Enchant\nand NeuralPLexer for multimodal endpoint prediction designed to improve the\nspeed, precision, and success rates of drug discovery and clinical\ndevelopment. At Iambic, we are building an engine that is designed to power\nthe future of medicine.\n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. All statements other than statements of\nhistorical or current fact included in this press release are forward-looking\nstatements, including but not limited to statements regarding the closing of\nthe public offering of common stock. In some cases, you can identify\nforward-looking statements because they contain words such as “may,”\n“expect,” “plan,” “anticipate,” “intend,” “estimate,” or\n“predict” or the negative of these words or other similar terms or\nexpressions that concern Iambic’s expectations, plans or intentions.\nForward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other factors. Some of these risks are\ndescribed in greater detail in the preliminary prospectus included in the\nRegistration Statement on Form S-1 filed with the SEC on October 8, 2026. It\nis not possible for our management to predict all risks, nor can we assess the\nimpact of all factors on our business or the extent to which any factor, or\ncombination of factors, may cause our actual results to differ materially from\nthose contained in any forward-looking statements we may make. These factors\nmay cause our actual results, performance or achievements to differ materially\nand adversely from those anticipated or implied by our forward-looking\nstatements. We undertake no obligation to update any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014222850/en/\n(https://www.businesswire.com/news/home/20261014222850/en/)\n\nMedia Contact: \n\nAmanda Guisbond\n\nHead of Communications, Iambic\n\namanda.guisbond@iambic.ai (mailto:amanda.guisbond@iambic.ai)\n\nInvestors: \n\nTiao Guan\n\nSr. Director, FP&A and Investor Relations, Iambic\n\ntiao.guan@iambic.ai (mailto:tiao.guan@iambic.ai)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8xSfqma-20261014","title":"Iambic Announces Pricing of Initial Public Offering","author":"Business Wire","ticker":"IAM","created":"2026-10-14T22:53:00.098Z","tickers":["IAM"],"exchange":"NASDAQ","article_body":"Iambic Announces Pricing of Initial Public Offering\n\nIambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life\nsciences and technology company advancing novel medicines using its AI-driven\nplatform, today announced the pricing of its initial public offering of\n9,375,000 shares of common stock at a public offering price of $16.00 per\nshare. All of the shares of common stock are being offered by Iambic. The\ngross proceeds from the offering, before deducting underwriting discounts and\ncommissions and other offering expenses payable by Iambic, are expected to be\n$150.0 million. In addition, Iambic has granted the underwriters a 30-day\noption to purchase up to an additional 1,406,250 shares of common stock at the\ninitial public offering price, less underwriting discounts and commissions.\nIambic’s common stock is expected to begin trading on the Nasdaq Global\nSelect Market on October 15, 2026, under the ticker symbol “IAM.” The\noffering is expected to close on October 16, 2026, subject to the satisfaction\nof customary closing conditions.\n\nJ.P. Morgan, Jefferies, BofA Securities and Citigroup are acting as joint\nbook-running managers for the offering.\n\nA registration statement relating to the offering has been filed with the\nSecurities and Exchange Commission and became effective on October 14, 2026.\nThe offering is being made only by means of a prospectus. A copy of the final\nprospectus, when available, relating to the offering will be available at\nwww.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54622422&newsitemid=20261014222850&lan=en-US&anchor=www.sec.gov&index=1&md5=06e0bce6dc5bafd4c7983d6fb5c076c6)\n. Copies of the final prospectus may also be obtained, when available, from:\nJ.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long\nIsland Avenue, Edgewood, New York 11717 or by email at\nprospectus-eq_fi@jpmchase.com (mailto:prospectus-eq_fi@jpmchase.com) ;\nJefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison\nAvenue, New York, New York 10022, by telephone at (877) 821-7388 or by email\nat Prospectus_Department@Jefferies.com\n(mailto:Prospectus_Department@Jefferies.com) ; BofA Securities, NC1-022-02-25,\nAttention: Prospectus Department, 201 North Tryon Street, Charlotte, North\nCarolina 28255-0001 or by email at dg.prospectus_requests@bofa.com\n(mailto:dg.prospectus_requests@bofa.com) ; or Citigroup Global Markets Inc.,\nc/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717 or by telephone at 1-800-831-9146.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation, or\nsale would be unlawful prior to the registration or qualification under the\nsecurities laws of any such state or jurisdiction.\n\nAbout Iambic\n\nIambic’s mission is to make better technology for better medicines. By\nutilizing molecular superintelligence — integrating proprietary AI with\nautomated, scalable chemistry and biology experimentation — our platform is\ndesigned to address the totality of drug discovery and development. We believe\nthe utility of our platform is demonstrated by the discovery of IAM1363, a\nnovel drug candidate advanced to clinic in approximately two years, along with\na diverse preclinical pipeline. Our leading AI technologies include Enchant\nand NeuralPLexer for multimodal endpoint prediction designed to improve the\nspeed, precision, and success rates of drug discovery and clinical\ndevelopment. At Iambic, we are building an engine that is designed to power\nthe future of medicine.\n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. All statements other than statements of\nhistorical or current fact included in this press release are forward-looking\nstatements, including but not limited to statements regarding the closing of\nthe public offering of common stock. In some cases, you can identify\nforward-looking statements because they contain words such as “may,”\n“expect,” “plan,” “anticipate,” “intend,” “estimate,” or\n“predict” or the negative of these words or other similar terms or\nexpressions that concern Iambic’s expectations, plans or intentions.\nForward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other factors. Some of these risks are\ndescribed in greater detail in the preliminary prospectus included in the\nRegistration Statement on Form S-1 filed with the SEC on October 8, 2026. It\nis not possible for our management to predict all risks, nor can we assess the\nimpact of all factors on our business or the extent to which any factor, or\ncombination of factors, may cause our actual results to differ materially from\nthose contained in any forward-looking statements we may make. These factors\nmay cause our actual results, performance or achievements to differ materially\nand adversely from those anticipated or implied by our forward-looking\nstatements. We undertake no obligation to update any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014222850/en/\n(https://www.businesswire.com/news/home/20261014222850/en/)\n\nMedia Contact: \n\nAmanda Guisbond\n\nHead of Communications, Iambic\n\namanda.guisbond@iambic.ai (mailto:amanda.guisbond@iambic.ai)\n\nInvestors: \n\nTiao Guan\n\nSr. Director, FP&A and Investor Relations, Iambic\n\ntiao.guan@iambic.ai (mailto:tiao.guan@iambic.ai)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-14T22:53:00.150944025Z","server_sent_at_ms":1792018380150},"received_at":"2026-10-14T22:53:00.201Z","source_url":"https://www.businesswire.com/news/home/20261014222850/en/"},"analysis":{"id":"157891","press_release_id":"169661","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for expected gross proceeds of $150.0 million.\n\nUnderwriters hold a 30-day option on up to 1,406,250 additional shares. The stock begins trading on Nasdaq under ticker IAM on October 15, with closing expected October 16.\n\nJ.P. Morgan, Jefferies, BofA Securities and Citigroup are joint book-running managers. Proceeds fund a clinical-stage pipeline led by IAM1363, discovered via the company's AI platform in roughly two years.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"AI drug discovery firm Iambic raises $150M in Nasdaq debut at $16/share."},"keyFigures":{"dealValueUsd":150000000,"offeringPrice":16,"sharesOffered":9375000,"customDimensions":{"closing_date":"2026-10-16","listing_date":"2026-10-15","greenshoe_days":30,"greenshoe_shares":1406250}},"namedEntities":{"people":[{"name":"Amanda Guisbond","role":"Head of Communications"},{"name":"Tiao Guan","role":"Sr. Director, FP&A and Investor Relations"}],"products":["IAM1363","Enchant","NeuralPLexer"],"companies":[{"name":"Iambic Therapeutics, Inc.","ticker":"IAM","relationship":"issuer"},{"name":"J.P. Morgan","relationship":"lead underwriter"},{"name":"Jefferies","relationship":"underwriter"},{"name":"BofA Securities","relationship":"underwriter"},{"name":"Citigroup","relationship":"underwriter"}],"dollarAmounts":[{"amount":"$150.0 million","context":"gross proceeds of IPO before underwriting discounts and expenses"},{"amount":"$16.00","context":"per-share public offering price"}]},"materialImpact":{"score":3,"reasoning":"IPO pricing for a clinical-stage AI drug discovery company: $150.0M gross proceeds at $16.00/share, a meaningful capital event but not a market-moving surprise since pricing was the expected outcome."},"tickerRelevance":{"others":[],"primary":"IAM"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"new-listing-small-cap","eventGravity":"IPO-pricing","sectorWeight":"biotech-AI-theme","householdBrandBoost":0,"retailFavoriteBoost":"moderate-AI-thesis"}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":3,"narrative":"Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for expected gross proceeds of $150.0 million.\n\nUnderwriters hold a 30-day option on up to 1,406,250 additional shares. The stock begins trading on Nasdaq under ticker IAM on October 15, with closing expected October 16.\n\nJ.P. Morgan, Jefferies, BofA Securities and Citigroup are joint book-running managers. Proceeds fund a clinical-stage pipeline led by IAM1363, discovered via the company's AI platform in roughly two years.","key_figures":{"dealValueUsd":150000000,"offeringPrice":16,"sharesOffered":9375000,"customDimensions":{"closing_date":"2026-10-16","listing_date":"2026-10-15","greenshoe_days":30,"greenshoe_shares":1406250}},"named_entities":{"people":[{"name":"Amanda Guisbond","role":"Head of Communications"},{"name":"Tiao Guan","role":"Sr. Director, FP&A and Investor Relations"}],"products":["IAM1363","Enchant","NeuralPLexer"],"companies":[{"name":"Iambic Therapeutics, Inc.","ticker":"IAM","relationship":"issuer"},{"name":"J.P. Morgan","relationship":"lead underwriter"},{"name":"Jefferies","relationship":"underwriter"},{"name":"BofA Securities","relationship":"underwriter"},{"name":"Citigroup","relationship":"underwriter"}],"dollarAmounts":[{"amount":"$150.0 million","context":"gross proceeds of IPO before underwriting discounts and expenses"},{"amount":"$16.00","context":"per-share public offering price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T22:53:04.554Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"new-listing-small-cap","eventGravity":"IPO-pricing","sectorWeight":"biotech-AI-theme","householdBrandBoost":0,"retailFavoriteBoost":"moderate-AI-thesis"}},"durationMs":null,"modelName":"glm-5.3-flashx"}}